Supportive Care | Specialty

The OncLive Supportive Care condition center page is a comprehensive resource for clinical news and expert insights on supportive care and management of patients with cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, best practices, and ongoing research as it relates to supportive care for patients with cancer.

Forging a New Field

November 25th 2022

Almost single-handedly, Jennifer Temel, MD, defined a research field in medicine, creating a new focus on quality of life for patients and survivors.

FDA Approves Eflapegrastim for Chemo-Induced Neutropenia

September 9th 2022

The FDA has approved eflapegrastim-xnst injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.

Practical Considerations for Fellows Treating VTE

July 11th 2022

Most hematology/oncology fellows will care for patients with venous thromboembolism throughout their training and long after their graduation from fellowship. Here are some practical considerations when treating a patient with an acute VTE.

Bringing Creativity to Science: Dawn L. Hershman Is a Giant of Cancer Care

April 1st 2022

For Dawn Hershman, MD, MS, research and medicine are art forms that she uses to uplift and inspire every day.

Investigators Navigate the Complicated Treatment Landscape of Chemotherapy-Induced Neutropenia

January 19th 2022

Advances in the treatment of solid tumors and hematologic malignancies have resulted in the development of thera-peutic regimens that can be administered at various points in a patient’s care.

Assessing Bleeding Disorders: Keys for Hem/Onc Fellows

December 27th 2021

Michelle Chi, MD and Jennifer R. Green, MD, share practical points for trainees to approach the initial evaluation for a bleeding-disorder patient.

FDA Greenlights Maribavir for Select Post-Transplant Recipients With CMV

November 24th 2021

The FDA has approved maribavir for the treatment of adult and pediatric patients aged 12 years and older weighing at least 35 kg who have post-transplant cytomegalovirus infection that does not respond to available antiviral treatment.

A Primer on Rising Medical Cannabis Use in Oncology

November 5th 2021

Unsurprisingly, the use of cannabis in patients with cancer appears to be increasing as more and more states are adopting cannabis legislation, both for medical and adult use.

Roxadustat Shows Activity Against Chemotherapy-Induced Anemia in Non-Myeloid Malignancies

August 26th 2021

The first-in-class small molecule HIF-PHI inhibitor roxadustat demonstrated promising efficacy with favorable tolerability when used in the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies, meeting the primary end point of the phase 2 WHITNEY trial.

FDA Issues a Complete Response Letter for Eflapegrastim for Chemo-Induced Neutropenia

August 6th 2021

The FDA has issued a complete response letter to Spectrum Pharmaceuticals regarding the biologics license application for eflapegrastimas a potential option for the management of chemotherapy-induced neutropenia.

ACCC Tool Gives Individualized Guidance for Geriatric Assessment Implementation in Patients With Cancer

June 2nd 2021

Melissa (Kah Poh) Loh, BMedSci, MBBCh, BAO, discusses the challenges of utilizing geriatric assessment in oncology and steps that the ACCC resources can provide to institutions that want to incorporate geriatric assessment into practice.

FDA Grants Priority Review to Maribavir for Select Post-Transplant Recipients With CMV

May 21st 2021

The FDA has accepted a new drug application for maribavir for the treatment of post-transplant recipients with cytomegalovirus infection who are refractory and/or resistant to previous anti-CMV treatment.

Plinabulin/Pegfilgrastim Combo Reduces Rate of Chemotherapy-Induced Neutropenia

November 16th 2020

November 16, 2020 - The combination of plinabulin and pegfilgrastim showed a statistically significant improvement in the rate of prevention of grade 4 neutropenia versus pegfilgrastim alone in patients with cancer undergoing chemotherapy.

Trilaciclib Reduces Need for G-CSF, RBC Transfusions From Chemo-Induced AEs in ES-SCLC

October 19th 2020

Treatment with the CDK4/6 inhibitor trilaciclib prior to chemotherapy compared with placebo significantly reduced the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer.

Avatrombopag Falls Short in Chemotherapy-Induced Thrombocytopenia

October 9th 2020

Avatrombopag failed to meet the composite primary end point of avoiding platelet transfusions, chemotherapy dose reductions by 15% or greater, and chemotherapy dose delays by 4 days or more in patients with solid tumors and chemotherapy-induced thrombocytopenia.

Managing High-Dose Methotrexate Toxicity

October 1st 2020

Smith-Stanley Shares Strategies to Address Gender Disparities in Oncology

September 30th 2020

To address disparities, it is important for institutions to embrace and promote the fostering of an inclusive culture and environment for healthcare professionals of all races and genders, and to adequately equip women specifically with the tools they need to achieve success in the field.

Plinabulin Shows Efficacy in Chemo-Induced Neutropenia Prevention During COVID-19 Era

September 29th 2020

Plinabulin was found to be a more favorable option for the prevention of chemotherapy-induced neutropenia compared with pegfilgrastim during the coronavirus disease 2019 pandemic.

From the Ophthalmologist’s Eye: Managing Ocular Toxicities With Belantamab Mafodotin in Myeloma

September 25th 2020

Shaily Shah, MD, discusses disease and treatment-related ocular toxicities that can arise in patients with cancer, specific management strategies for patients receiving belantamab mafodotin who develop ocular toxicities, and the importance of collaborative management of these patients.

FDA Grants Breakthrough Therapy Designation to Plinabulin for Chemotherapy-Induced Neutropenia

September 10th 2020

The FDA has granted a breakthrough therapy designation to plinabulin for chemotherapy-induced neutropenia.